The SAFA trial is funded by the NIHR HTA programme to determine the clinical and cost-effectiveness spironolactone compared with placebo in addition to standard care in the treatment of moderate or severe persistent facial acne in adult women.
SAFA is a pragmatic multicentre double-blind randomised placebo-controlled trial recruiting from dermatology centres in Birmingham, Bristol, Cardiff, Epsom, Harrogate, London, Nottingham, Poole, Portsmouth and Swansea. General practices local to the sites will act as Participant Identification Centres.
We recruited 410 women aged 18 years and over.
Recruitment began in June 2019 and the results of the study were published in the British Medical Journal in May 2023, showing that spironolactone is an effective alternative to antibiotic treatments for female adult acne.
The SAFA study has now finished and participants are no longer being recruited.
For general queries about the study, please contact the SAFA study team.
Email: safa@soton.ac.uk
Telephone: 02381205538
Postal address:
Southampton Clinical Trials Unit
University of Southampton
Mailpoint 131
Southampton General Hospital
Tremona Road
Southampton
SO16 6YD